Alendrate

Pays: Nouvelle-Zélande

Langue: anglais

Source: Medsafe (Medicines Safety Authority)

Ingrédients actifs:

Alendronate sodium trihydrate 13.05mg Equivalent to 10 mg alendronic acid;  

Disponible depuis:

Viatris Limited

DCI (Dénomination commune internationale):

Alendronate sodium trihydrate 13.05 mg (Equivalent to 10 mg alendronic acid)

Dosage:

10 mg

forme pharmaceutique:

Tablet

Composition:

Active: Alendronate sodium trihydrate 13.05mg Equivalent to 10 mg alendronic acid   Excipient: Croscarmellose sodium Lactose monohydrate Magnesium stearate Microcrystalline cellulose Povidone

Unités en paquet:

Blister pack, PVC/aluminium, 30 tablets

classe:

Prescription

Type d'ordonnance:

Prescription

Fabriqué par:

Pharmaceutical Works Polpharma SA

indications thérapeutiques:

Alendrate is indicated: · In postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · In postmenopausal women who are at risk of developing osteoporosis Alendrate is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · For the treatment of osteoporosis in men to prevent fractures. · For the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · For treatment of Paget's disease of bone in men and women.

Descriptif du produit:

Package - Contents - Shelf Life: Blister pack, PVC/aluminium - 30 tablets - 36 months from date of manufacture stored at or below 25°C

Date de l'autorisation:

2004-04-19